D. E. Shaw & Co., Inc. Abb Vie Inc. Put Options Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

Put Options

29 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $4.6 Million - $5.6 Million	-28,100 Reduced 16.92%	138,000 $27.3 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $11.3 Million - $13.2 Million	72,800 Added 78.03%	166,100 $28.5 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $53.3 Million - $60.8 Million	-333,800 Reduced 78.15%	93,300 $17 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $17.3 Million - $19.5 Million	125,700 Added 41.71%	427,100 $66.2 Million
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $30 Million - $34.7 Million	-224,300 Reduced 42.67%	301,400 $44.9 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $21.6 Million - $26.9 Million	163,200 Added 45.02%	525,700 $70.8 Million
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $4.64 Million - $5.35 Million	32,100 Added 9.72%	362,500 $57.8 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $2.92 Million - $3.5 Million	21,100 Added 6.82%	330,400 $53.4 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $127 Million - $146 Million	-948,900 Reduced 75.42%	309,300 $41.5 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $42.6 Million - $54.1 Million	-309,400 Reduced 19.74%	1,258,200 $193 Million
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $128 Million - $158 Million	966,700 Added 160.88%	1,567,600 $254 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $4.62 Million - $5.84 Million	-43,000 Reduced 6.68%	600,900 $81.4 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $2.84 Million - $3.22 Million	-26,700 Reduced 3.98%	643,900 $69.5 Million
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $16.7 Million - $18.6 Million	159,100 Added 31.1%	670,600 $75.5 Million
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $81.8 Million - $90.1 Million	-799,678 Reduced 60.99%	511,500 $55.4 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $21.2 Million - $28.6 Million	263,200 Added 25.12%	1,311,178 $140 Million
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $41.4 Million - $48.6 Million	482,100 Added 85.2%	1,047,978 $91.8 Million
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $926,076 - $1.24 Million	-12,622 Reduced 2.18%	565,878 $55.6 Million
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $1.41 Million - $2.13 Million	-21,800 Reduced 3.63%	578,500 $44.1 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $24.5 Million - $30.6 Million	-339,200 Reduced 36.1%	600,300 $53.2 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $32.2 Million - $38.7 Million	511,100 Added 119.3%	939,500 $71.1 Million
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $30.1 Million - $38.5 Million	-458,500 Reduced 51.7%	428,400 $31.2 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $26.6 Million - $31.3 Million	345,200 Added 63.73%	886,900 $71.5 Million
Q4 2018 Feb 14, 2019	BUY	$77.85 - $96.01 $2.67 Million - $3.29 Million	34,300 Added 6.76%	541,700 $49.9 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $10.5 Million - $11.6 Million	117,600 Added 30.17%	507,400 $48 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $6.84 Million - $8.09 Million	76,200 Added 24.3%	389,800 $36.1 Million
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $14.3 Million - $19.1 Million	-155,200 Reduced 33.11%	313,600 $29.7 Million
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $39.7 Million - $43.6 Million	443,600 Added 1760.32%	468,800 $45.3 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $1.76 Million - $2.25 Million	25,200	25,200 $2.24 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account